MCKESSON CORP Annual Report - How They Did This Year

I’ve put together a plain-English guide to help you understand McKesson Corp’s performance this year. Instead of digging through dense financial filings, I’ve broken down the key takeaways to help you decide if this company fits your investment goals.

1. What does this company do?

McKesson acts as the "operating system" for modern healthcare. They are the massive middleman that keeps the medical world moving. They distribute drugs and medical supplies while providing the technology that helps pharmacies, hospitals, and doctors manage their daily operations. They make money by buying medicine from manufacturers and selling it to retail pharmacies, hospitals, and health systems.

2. How are they organized?

As of 2026, they have organized their business into four clear areas:

• North American Pharmaceutical: Their core business of distributing branded, generic, and specialty drugs across the U.S. and Canada.
• Oncology & Multispecialty: A high-growth area focused on cancer care and gene therapy, anchored by the U.S. Oncology Network.
• Prescription Technology Solutions: Software that helps patients afford medication and assists doctors and pharmacies with insurance, billing, and patient care.
• Medical-Surgical Solutions: Supplies for non-hospital settings like surgery centers and physician offices, including clinical and laboratory equipment.

3. Big Changes: A Major Pivot

The biggest news is that McKesson plans to spin off its Medical-Surgical Solutions segment into an independent company. They already secured a $1.25 billion investment from Apollo Global Management for a minority stake in that division. This move simplifies the company and lets them focus on their core pharmaceutical and technology strengths. They also sold their operations in Norway, completing their exit from European markets to focus on higher-profit specialty and tech segments in North America.

4. Financial Health: The "Engine"

McKesson is a financial powerhouse that uses a data-driven approach to cut waste and improve efficiency. They aren't just moving boxes; they use high-tech tools like McKesson Connect for inventory management and Central Fill for automated prescription refills to keep profits healthy. These efficiencies provide the cash to pay down debt, buy back shares, and invest in growth. They maintain a strong balance sheet and a high credit rating to ensure they can always access capital.

5. Major Wins and Risks

• Wins: They are successfully shifting from a "box-mover" to a "tech-partner." Their specialty care network is a massive competitive advantage that is difficult for rivals to replicate. It integrates clinical research, practice management, and drug distribution.
• Risks: They rely heavily on a small group of large customers, like national pharmacy chains. If they lost one of these partners, it would significantly hurt their total sales. They are also at the mercy of government drug pricing policies, which can change the rules of the game overnight.

6. Future Outlook

Management is doubling down on specialty care and technology. They want to be the essential partner for drug companies and pharmacies by helping them navigate complex insurance and distribution challenges. Their strategy uses their massive scale to sell more technology services, making their customer relationships "stickier" and driving long-term value.

Decision Checklist: Before you invest, ask yourself:

• Do I believe in the shift toward specialty care and high-margin tech services?
• Am I comfortable with the risks associated with government drug pricing and large-customer concentration?
• Does the upcoming spin-off of the Medical-Surgical segment align with my view of a leaner, more focused company?

Note: This guide provides a high-level overview. For deep-dive analysis, the full 10-K filing is available on the SEC website.